Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.

Leukemia research - 1 Nov 2005

Moravcová Jana, Rulcová Jana, Polák Jaroslav, Zemanová Zuzana, Klamová Hana, Haskovec Cedrik

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Cytogenetic Analysis
Share to Fusion Proteins, bcr-abl
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Pyrimidines

Share to Remission Induction

Source

Identifiers

PMID: 15876454
DOI: 10.1016/j.leukres.2005.04.001

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.PMID 15876454Read ↗

A Rare e14a3 (b3a3) BCR-ABL Fusion Transcript in Chronic Myeloid LeukemiaSemantic proximity Read ↗

A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD)Semantic proximity Read ↗

Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.Semantic proximity Read ↗

Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of KashmirSemantic proximity Read ↗

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.Semantic proximity Read ↗

A review on characterization of BCR - ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes.Semantic proximity Read ↗

Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy.Semantic proximity Read ↗

[Chronic myeloid leukemia with variant e19a2 BCR-ABL1 fusion transcript: interest of the molecular identification at diagnosis for minimal residual disease follow-up].Semantic proximity Read ↗

Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes.Semantic proximity Read ↗

[BCR-ABL T315I mutant acute lymphoblastic leukemia in 3 children].Semantic proximity Read ↗

Imatinib resistance in chronic myeloid leukemia due to a rare mutation.Semantic proximity Read ↗

Prevalence and outcomes of uncommon BCR ‐ ABL 1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centreSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.